// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).

Maha Hussain - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Patterns of prostate cancer management across Canadian prostate cancer treatment specialists.

Bobby Shayegan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).

Jonathan E. Rosenberg - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Enfortumab vedotin

FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis.

Sidra Khalid - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Overcoming miR-106a induced radioresistance in prostate cancer: Targeting senescence with KU-55933.

Christianne Hoey - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

KU-55933

Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results.

Gillian Vandekerkhove - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Pembrolizumab

Impact of bone metastasis on clinical outcomes in metastatic urothelial bladder cancer (mUC) for patients treated with first-line platinum-based chemotherapy.

Jamila Jama Almi Riromar - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bone metastases

N/A

First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).

Archana Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

N/A

Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.

Archana Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

N/A

Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).

Pier Vitale Nuzzo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Comparative effectiveness of a patient-centered prostate biopsy report in clinical prostate cancer practice.

Jasmir G. Nayak - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.

Gillian Vandekerkhove - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

N/A

Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry.

John L. Gore - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity.

Joelle Helou - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer.

Michal Sarfaty - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.

Guru Sonpavde - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Atezolizumab

Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).

Di Maria Jiang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Prostate cancer

Androgen Tear

Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).

Archana Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

N/A

Contribution of microRNA-200b-3p to radiation therapy resistance in 22RV1 prostate cancer cells.

John Thoms - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Cross-trial comparison of taxane versus non-taxane combination chemotherapy regimens for advanced penile cancer (APC): A systematic review.

Esmail Mutahar Al-Ezzi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Penile carcinoma

Carboplatin

Copyright © 2026. QuantiNova All rights reserved